Abstract: A system for individual dosing of a medicament, in accordance with the individual pathological properties (“fingerprint”) of a patient—corresponding physiologically or genetically to the disease status is based on two components: the medicament that is to be taken or administered in a variable individual dosage and a miniaturized indicator system that obtains information from blood, saliva or other bodily fluids and tissues of the patient and displays the information in a readable form so that the patient or the treating physician can immediately read the optimal active substance to be taken or dosage to be administered.

Abstract: A phospholipid gel is spontaneously formed when combining a first phospholipid, a second phospholipid, and water, wherein the first phospholipid is a neutral phospholipid and the second phospholipid is a negatively charged phospholipid. The first and second phospholipids are of natural origin, semi-synthetic origin, or synthetic origin. Preferably, they are di(C8-C22 acyl) phosphatidyl choline and di(C8-C22 acyl) phosphatidyl glycerol. The total phospholipid concentration is within a range of 6-40% by weight.

Abstract: A system for individual dosing of a medicament, in accordance with the individual pathological properties (“fingerprint”) of a patient—corresponding physiologically or genetically to the disease status is based on two components: the medicament that is to be taken or administered in a variable individual dosage and a miniaturized indicator system that obtains information from blood, saliva or other bodily fluids and tissues of the patient and displays the information in a readable form so that the patient or the treating physician can immediately read the optimal active substance to be taken or dosage to be administered.

Abstract: A bisphosphonic acid of the general formula (I) wherein R1 is H, OH, C1-C6 alkyl C1-C6 alkoxy, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 halogen alkyl X is a direct bond, alkylen group with 1 to 20 carbon atoms, (CH3)m—(OCR3HCH2)n—(O)o—, wherein R3 is H or CH3 and m is 0 or a number from 1 to 6, n is a number from 1 to 10, preferably 1 to 6, and o is 0 or 1, —(CR4HCH2O)p—, wherein R4 is H or CH3, p is a number from 1 to 10, preferably 1 to 6, (CH3)q—(OCR5HCH2)r—(O)s—(CH3)t—, wherein R5 is H or CH3 and q is 0 or a number from 1 to 6, r is a number from 1 to 10, preferably 1 to 6, and s is 0 or 1, and t is a number from 1 to 6, R2 is a group of the formula (II) as well as their physiologically compatible derivatives in particular salts and trimethyl silyl derivatives.

Abstract: A bisphosphonic acid of the general formula (I) wherein R1 is H, OH, C1-C6 alkyl C1-C6 alkoxy, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 halogen alkyl X is a direct bond, alkylen group with 1 to 20 carbon atoms, (CH3)m—(OCR3HCH2)n—(O)o— wherein R3 is H or CH3 and m is 0 or a number from 1 to 6, n is a number from 1 to 10, preferably 1 to 6, and o is 0 or 1, ?—(CR4HCH2O)p— wherein R4 is H or CH3, p is a number from 1 to 10, preferably 1 to 6, ?(CH3)q—(OCR5HCH2)r—(O)s—(CH3)t—, wherein R5 is H or CH3 and q is 0 or a number from 1 to 6, r is a number from 1 to 10, preferably 1 to 6, and s is 0 or 1, and t is a number from 1 to 6, R2 is a group of the formula (II) as well as their physiologically compatible derivatives, in particular salts and trimethyl silyl derivatives.

Abstract: In a system for individual dosing of a medicament, in accordance with the individual pathological properties (“fingerprint”) of a patient—corresponding physiologically or genetically to the disease status—two components are provided: a medicament that is to be taken or administered in a variable individual dosage and a miniaturized indicator system that obtains information from blood, saliva or other bodily fluids and tissues of the patient and displays the information in a readable form so that the patient or the treating physician can immediately read the optimal active substance to be taken or dosage to be administered.